COVID-19 Rapid POC CE-IVD Test

In light of the impact from SARS-CoV-2 and COVID-19, we have seen an increasing demand for reagents essential to lateral flow assays and point-of-care test development from our customers. Rapid diagnosis is a critical tool for screening at-risk populations and managing the spread of the outbreak. Development of sensitive lateral flow assays requires high performance, robust gold particles, and our BioReady gold reagents are a key component for maximizing the sensitivity and reliability of visual detection point of care tests.